NTLA Q1 2020 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+23.8% YoY

Gross Profit

-$22M-168.3% margin

Operating Income

-$33M-255.9% margin

Net Income

-$32M-246.3% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

+18.1%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$315M

Total Liabilities

$67M

Stockholders' Equity

$248M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$10M	+23.8%
Gross Profit	-$22M	-$13M	-63.7%
Operating Income	-$33M	-$24M	-38.8%
Net Income	-$32M	-$22M	-45.0%